Cambridge, MA, United States of America

Melissa Chin

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Editas Medicine, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Melissa Chin. Retrieved from https://idiyas.com/inventor/melissa-chin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Melissa Chin

Introduction

Melissa Chin is a prominent inventor based in Cambridge, MA (US). She has made significant strides in the field of immunotherapy through her innovative work. Her research focuses on the application of CRISPR-Cas9 technology, which has the potential to revolutionize treatments for various diseases.

Latest Patents

Melissa Chin holds a patent titled "Methods, Compositions and Components for CRISPR-Cas9 Editing of TGFBR2 in T Cells for Immunotherapy." This patent represents her groundbreaking contributions to the field and highlights her expertise in genetic editing.

Career Highlights

Chin is currently employed at Editas Medicine, Inc., a leading company in the field of gene editing. Her work at Editas has positioned her as a key player in the development of innovative therapies that harness the power of CRISPR technology.

Collaborations

Throughout her career, Melissa has collaborated with notable colleagues, including Stephen Michael Burleigh and Fred Harbinski. These partnerships have further enhanced her research and contributed to the advancement of immunotherapy.

Conclusion

Melissa Chin's contributions to the field of immunotherapy through her innovative patent and work at Editas Medicine, Inc. underscore her role as a leading inventor in genetic editing. Her research continues to pave the way for new therapeutic approaches that could benefit countless patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…